Bing Yao is the founder of ArriVent Biopharma. ArriVent Biopharma has raised $150M in total funding. Latest round: Series A.
Bing (Zhengbin) Yao is the CEO and Chairman of the Board at ArriVent Biopharma, a Pennsylvania-based biopharmaceutical company focused on developing furmonertinib for lung cancer. He is described as a biopharma veteran involved in the company's launch and financing.
Full founder directory · Investor directory · Company funding database · Fundraising library